Home News and Events Press Release
Press Release
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
Learn MoreArgo Biopharma Completes First Patient Dosing for Phase II Clinical Trial in Chronic Hepatitis B
Learn MoreArgo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
Learn MoreArgo Biopharma Receives IND Approval for Phase II Clinical Trial of Promising siRNA-PEG-IFNα Combination Therapy in Chronic Hepatitis B
Learn MoreArgo Biopharma Announces First Subject Dosed in Phase I Clinical Trial of an Investigational siRNA Therapy BW-40202 Targeting Complement Factor B
Learn MoreArgo Biopharma’s Novel siRNA Therapeutic BW-20507 Granted Breakthrough Therapy Designation in China for Chronic Hepatitis B Virus Infection
Learn MoreArgo Biopharma Announces Phase 2 Advancement and Milestone Payment for siRNA Molecule BW-00163
Learn More
为了更好的呈现效果，移动端请竖屏浏览
